(Q38387890)

2 September 2017

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. (English)

1 reference

2 September 2017

1 reference

7

Elizabeth R Unger

1 reference

2 September 2017

15

Lauri E Markowitz

1 reference

2 September 2017

2

Nancy M Bennett

1 reference

2 September 2017

3

Linda M Niccolai

1 reference

2 September 2017

1

Susan Hariri

1 reference

2 September 2017

14

Martin Steinau

1 reference

2 September 2017

4

Sean Schafer

1 reference

2 September 2017

10

Mary W Scahill

1 reference

2 September 2017

9

Pamela Julian

1 reference

2 September 2017

11

Nasreen Abdullah

1 reference

2 September 2017

12

Diane Levine

1 reference

2 September 2017

8

Erin Whitney

1 reference

2 September 2017

HPV-IMPACT Working Group

series ordinal

16

object named as

HPV-IMPACT Working Group

1 reference

2 September 2017

Ina U Park

5

1 reference

2 September 2017

Karen C Bloch

series ordinal

6

1 reference

2 September 2017

Michelle L Johnson

series ordinal

13

1 reference

2 September 2017

language of work or name

English

0 references

publication date

11 February 2015

1 reference

2 September 2017

6

1 reference

inferred from page(s)

published in

Vaccine

1 reference

2 September 2017

33

1 reference

2 September 2017

1608-1613

1 reference

2 September 2017

13

1 reference

Epidemiology's contributions to a Nobel Prize recognition

2 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Population impact of HPV vaccines: summary of early evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Human papillomavirus and cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

7 January 2021

inferred from DOI database lookup

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.01.084

Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States

7 January 2021

1 reference

12 December 2020

Chapter 1: HPV in the etiology of human cancer

1 reference

12 December 2020

Cervical cancer screening among women aged 18-30 years - United States, 2000-2010

1 reference

12 December 2020

Noninfluenza vaccination coverage among adults - United States, 2011.

1 reference

12 December 2020

FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2013

1 reference

12 December 2020

10.1016/J.VACCINE.2015.01.084

Identifiers

DOI

1 reference

2 September 2017

0 references

1 reference